Benign Prostatic Hyperplasia Pipeline Highlights Report 2017 - ResearchAndMarkets.com

DUBLIN--()--The "Benign Prostatic Hyperplasia Pipeline Highlights - 2017 Update" drug pipelines has been added to ResearchAndMarkets.com's offering.

Benign Prostatic Hyperplasia Pipeline Highlights - 2017 Update, provides most up-to-date information on key pipeline products in the global Benign Prostatic Hyperplasia market.

It covers emerging therapies for Benign Prostatic Hyperplasia in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives in tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Benign Prostatic Hyperplasia pipeline products by clinical trial stages, including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Benign Prostatic Hyperplasia pipeline products by their dominant mechanism of action. This helps executives to categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Benign Prostatic Hyperplasia pipeline products by the company.

Short-term Launch Highlights:

Find out which Benign Prostatic Hyperplasia pipeline products will be launched in the US and ex-US till 2020.

Summary:

  • Benign Prostatic Hyperplasia phase 3 clinical trial pipeline products
  • Benign Prostatic Hyperplasia phase 2 clinical trial pipeline products
  • Benign Prostatic Hyperplasia phase 1 clinical trial pipeline products
  • Benign Prostatic Hyperplasia preclinical research pipeline products
  • Benign Prostatic Hyperplasia discovery stage pipeline products
  • Benign Prostatic Hyperplasia pipeline products short-term launch highlights

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wtmzrx/benign_prostatic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs